The first case of COVID-19 in China was reported in December 2019. Since then, the country has reported 83,912 cases, and 4,637 deaths, according to the data from US based John Hopkins Institute. The outbreak has brought terrible public health crisis and significant economic costs. According to the official data released, China’s Gross Domestic Product (GDP) fell 6.8 per cent in January- March year-on-year, a slightly larger decline than the 6.5 per cent forecast by analysts and reversing a 6 per cent expansion in the fourth quarter of 2019. It was the first contraction in the world’s second-largest economy since 1992. According to the International Monetary Fund (IMF), China is expected to grow by 1.2 per cent this year. In January 2020, the firm had predicted a 6 per cent growth. However, all is not lost, the country is expected to see a rebound in activity later this year, with growth bouncing back to 9.2 per cent next year, the IMF predicts. This all could have a ripple effect in the healthcare sector of the country.
Post COVID-19 Chinese Healthcare
Healthcare sector ranks eighth in China, and the epidemic has shed light on the areas which need to be improved. There’s no doubt this will have a profound impact on the several subsectors related to the industry.
Healthcare reform will speed up in the coming months, especially strengthening of the primary care system and integration with public health crisis management system. There will be further improvements on the sustainability and affordability of the social medical insurance funds.
This story is from the May 2020 edition of BioSpectrum Asia.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the May 2020 edition of BioSpectrum Asia.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber? Sign In
Ushering Fourth Industrial Revolution in Telangana
Taking advantage of the 21st edition of BioAsia 2024 at the Hyderabad International Convention Centre (HICC) in Madhapur, the Government of Telangana, a southern state in India, leveraged the confluence of the global platform to spearhead initiatives aimed at propelling the state into the forefront of the Fourth Industrial Revolution (C4IR).
How Indian Biotech Investments are on a Doubling Spree
A latest report by Ankur Capital provides a closer look at the investments made in biotechnology in the last decade in the country.
"AI will be integrally involved in not only the diagnosis of cancer but also in determining the prognosis and best therapeutic option”
South Korea-based Deep Bio, a pioneering artificial intelligence (AI) healthcare firm focused on cancer pathology, is making waves in the industry.
"Because of its specificity and selectivity, ADCS have the potential to reduce adverse side effects and improve patient survival"
Japan-headquartered Daiichi Sankyo, the global healthcare company, launched its subsidiary Daiichi Sankyo Singapore Pte. Ltd. to bridge unmet needs in oncology.
Can Test, Treat, Track Beat Malaria?
Malaria has long been a major public health concern in the Asia Pacific region, particularly in South East Asia (SEA) affecting millions of people.
Engineering CAR T cell sharpshooters
Approved CAR T-cell therapies have shown remarkable results in patients with certain types of blood cancers.
Addressing Challenges in Cell Therapy Manufacturing
Even with significant advancements, there are still anumber of issues with cell therapy manufacturing that need to be resolved as production grows.
"We anticipate India will adopt decentralised models for managing CGTs, ensuring closer proximity between patients and treatment facilities"
Cell and gene therapy (CGT) expert from Germany, Miltenyi Biotec has recently announced its entry into the Indian market to provide researchers, scientists and clinicians easier access to expertise, research, and manufacturing solutions.
Addressing Accessibility and Affordability of CELL & GENE THERAPIES
Cell and gene therapies (CGT) are one of the hottest sectors in the pharmaceutical industry.
Korea designs sweat resistant wearable robot sensor
New electromyography (EMG) sensor technology that allows the long-term stable control of wearable robots and is not affected by the wearer's sweat and dead skin has gained attention recently.
